The eIF2-alpha kinase HRI: a potential target beyond the red blood cell.
The eIF2-alpha kinase HRI: a potential target beyond the red blood cell.
复制标题
DOI:
10.1080/14728222.2017.1397133
复制
发表时间:
2017-12
影响因子:
5.8
通讯作者:
Aktas BH
中科院分区:
文献类型:
--
作者:
Burwick N;Aktas BH
The eIF2α kinase heme-regulated inhibitor (HRI) is one of four well-described kinases that phosphorylate eIF2α in response to various cell stressors, resulting in reduced ternary complex formation and attenuation of mRNA translation. Although HRI is well known for its role as a heme sensor in erythroid progenitors, pharmacologic activation of HRI has been demonstrated to have anti-cancer activity across a wide range of tumor sub-types. Here, the potential of HRI activators as novel cancer therapeutics is explored. We provide an introduction to eIF2 signaling pathways in general, and specifically review data on the eIF2α kinase HRI in erythroid and non-erythroid cells. We review aspects of targeting eIF2 signaling in cancer and highlight promising data using HRI activators against tumor cells. Pharmacologic activation of HRI inhibits tumor growth as a single agent without appreciable toxicity in vivo. The ability of HRI activators to provide direct and sustained eIF2α phosphorylation without inducing oxidative stress or broad eIF2α kinase activation may be especially advantageous for tolerability. Combination therapy with established therapeutics may further augment anti-cancer activity to overcome disease resistance.
登录
查看更多内容
影响因子:
20.3
作者:
Hahn, Cynthia K.;Lowrey, Christopher H.
通讯作者:
Lowrey, Christopher H.
影响因子:
7.2
作者:
Dever TE;Green R
通讯作者:
Green R
DOI:
10.1126/science.aaa4484
发表时间:
2015-04-10
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Das I;Krzyzosiak A;Schneider K;Wrabetz L;D'Antonio M;Barry N;Sigurdardottir A;Bertolotti A
通讯作者:
Bertolotti A
影响因子:
--
作者:
Aktas BH;Qiao Y;Ozdelen E;Schubert R;Sevinc S;Harbinski F;Grubissich L;Singer S;Halperin JA
通讯作者:
Halperin JA
影响因子:
4.8
作者:
Berlanga, JJ;Herrero, S;de Haro, C
通讯作者:
de Haro, C